Specializes in the development of antibody-drug conjugates for the treatment of hematologic cancers and solid tumors.
ADC Therapeutics SA is a biotechnology company at the forefront of developing innovative antibody drug conjugates (ADCs) aimed at improving outcomes for patients with hematological malignancies and solid tumors. One of its key products, ZYNLONTA, is currently undergoing Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III trials in combination with rituximab for second-line transplant-ineligible patients with DLBCL. Additionally, ZYNLONTA is in Phase I trials for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, an ADC that has completed Phase I trials for relapsed or refractory NHL, is in Phase II trials for relapsed or refractory Hodgkin lymphoma, and Phase Ib trials for advanced solid tumors.
Beyond its marketed and advanced clinical-stage products, ADC Therapeutics is advancing several promising candidates. These include ADCT-602 in Phase Ia trials for acute lymphoblastic leukemia, ADCT-601 and ADCT-901 in Phase Ia trials for various solid tumors, and preclinical candidates such as ADCT-701 and ADCT-901 for solid tumor treatments. The company collaborates extensively with industry leaders including Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited, leveraging strategic partnerships to accelerate the development and commercialization of its ADC therapies.
Founded in 2011 and headquartered in Epalinges, Switzerland, ADC Therapeutics SA continues to expand its portfolio with a focus on pioneering ADCs that target specific cancer cells while sparing healthy tissue. With a robust pipeline and a commitment to innovation, the company aims to address significant unmet medical needs in oncology, offering new hope to patients worldwide.